Resources
6 Results (showing 1 - 6)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 3/25/2021 (updated 4/5/2024)
Effective Harm Reduction Strategies for People Who Actively Use Opioids and/or Psychostimulants
Participants will learn evidenced-based harm reduction strategies to keep people who use opioids and psychostimulants alive with reduced disease burden. Presenters will discuss methods of engaging people who actively use opioids and/or psychostimulants, harm reduction interventions, overdose prevention and response, overamping prevention and response, and linkages to care.
Posted 12/15/2020 (updated 4/3/2024)
This workshop presented strategies to integrate HIV, hepatitis, and sexual health concerns into services for PWID. The session focused on communication skills, assessment techniques, and building motivation to make healthier choices. The presentation looked at programmatic and clinical level integration strategies and offered participants a chance to assess current service delivery models and develop a plan to enhance care.
Posted 12/15/2020 (updated 4/3/2024)
Participants learned evidenced based harm reduction strategies to keep people who use drugs (PWUD) alive with reduced disease burden. Presenters discussed methods of engaging PWUD, linkages to MOUD, behavioral health and recovery supports for individuals ready for these supports
Posted 5/22/2020 (updated 3/28/2024)
To identify Finnegan Neonatal Abstinence Scoring Tool tems independently associated with the decision to use pharmacologic therapy and to simplify the FNAST while minimizing loss of information for the treatment decision.
Posted 7/26/2023 (updated 3/28/2024)
This session covered how primary prevention efforts fit within each of the various stages of the Continuum of Care Model. Attendees learned how to (1) engage community stakeholders from each of the 12 sectors and (2) evidence-based practices to not only inform, but to reduce stigma and to create open dialogue as it relates to SUD.
Posted 4/26/2022 (updated 3/27/2024)
Background: The US overdose crisis is driven by fentanyl, heroin, and prescription opioids. One evidence-based policy response has been to broaden naloxone distribution, but how much naloxone a community would need to reduce the incidence of fatal overdose is unclear. We aimed to estimate state-level US naloxone need in 2017 across three main naloxone access points (community-based programmes, provider prescription, and pharmacy-initiated distribution) and by dominant opioid epidemic type (fentanyl, heroin, and prescription opioid).